Acrivon Therapeutics (ACRV) Operating Expenses (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Operating Expenses of $19.9 million for Q1 2026, down 8.12% year-over-year from $21.7 million in Q1 2025, and down 1.06% quarter-over-quarter from $20.1 million in Q4 2025.
Acrivon Therapeutics (ACRV) Operating Expenses (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Operating Expenses for 6 consecutive years, with $19.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses fell 8.12% year-over-year to $19.9 million; the TTM figure through Mar 2026 stood at $82.4 million (down 11.63% YoY), while the FY2025 annual figure was $84.1 million, down 5.7% from the prior year.
- Operating Expenses declined to $19.9 million in Q1 2026 per ACRV's latest filing, from $20.1 million in the prior quarter.
- Across five years, Operating Expenses topped out at $25.1 million in Q3 2024 and bottomed at $5.9 million in Q2 2022.
- Historically, Operating Expenses has averaged $17.2 million across 5 years, with a median of $19.7 million in 2025.
- Annual changes were most pronounced in 2022 — Operating Expenses soared 258.48% — and 2025, when it fell 21.69%.
- Acrivon Therapeutics' Operating Expenses stood at $9.9 million in 2022, then surged by 111.69% to $21.1 million in 2023, then advanced by 18.53% to $25.0 million in 2024, then dropped by 19.39% to $20.1 million in 2025, then dropped by 1.06% to $19.9 million in 2026.
- Business Quant data shows ACRV's Operating Expenses at $19.9 million in Q1 2026, $20.1 million in Q4 2025, and $19.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Acrivon Therapeutics | 92.26 Mn | 92.26 Mn | - | 18.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.67 Mn |
| Mar 31, 2026 | 19.90 Mn |
| Dec 31, 2025 | 20.12 Mn |
| Sep 30, 2025 | 19.69 Mn |
| Jun 30, 2025 | 22.65 Mn |
| Mar 31, 2025 | 21.66 Mn |
| Dec 31, 2024 | 24.95 Mn |
| Sep 30, 2024 | 25.14 Mn |
| Jun 30, 2024 | 21.44 Mn |
| Mar 31, 2024 | 17.67 Mn |
| Dec 31, 2023 | 21.05 Mn |
| Sep 30, 2023 | 16.14 Mn |
| Jun 30, 2023 | 15.52 Mn |
| Mar 31, 2023 | 14.39 Mn |
| Dec 31, 2022 | 9.95 Mn |
| Sep 30, 2022 | 9.58 Mn |
| Jun 30, 2022 | 5.93 Mn |
| Mar 31, 2022 | 7.21 Mn |
| Dec 31, 2021 | 4.27 Mn |
| Sep 30, 2021 | 2.67 Mn |